✦ LIBER ✦

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

✍ Scribed by Hecht, J. R.; Trarbach, T.; Hainsworth, J. D.; Major, P.; Jager, E.; Wolff, R. A.; Lloyd-Salvant, K.; Bodoky, G.; Pendergrass, K.; Berg, W.; Chen, B.-L.; Jalava, T.; Meinhardt, G.; Laurent, D.; Lebwohl, D.; Kerr, D.

Book ID: 126643159
Publisher: American Society of Clinical Oncology
Year: 2011
Tongue: English
Weight: 175 KB
Volume: 29
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2010.29.4496

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3010 ORAL Final overall survival (OS) re

3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

✍ J.R. Hecht; T. Trarbach; E. Jaeger; J. Hainsworth; R.A. Wolff; K. Lloyd; G. Bodo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB